Condition: Childhood Leukemia · Sponsor: Chinese University of Hong Kong
Prognosis of children with leukemia, the most common pediatric cancer, has improved markedly. Yet, relapse still occurs in 15-40% of patients with a probability of survival of \<50%, which is unlikely to be boosted by intensification of standard chemotherapy due to overwhelming toxicity. The advent of effective and safe targeted therapies for high-risk cases is therefore imperative. This study constitutes two research projects aiming at driving therapeutic advances.
This description comes directly from the study's public registry record.
Kathy Chan, Ph. D. · 852-35052858 · kathyyychan@cuhk.edu.hk
Kam Tong Leung, Ph. D. · 852-35133176 · ktleung@cuhk.edu.hk
Always discuss trial participation with your own doctor first.
| Hong Kong Children Hospital | Hong Kong, Hksar, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04478006